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Background. Previous neuroimaging studies indicate abnormalities in cortico-limbic circuitry 
in mood disorder. Here we employ prospective longitudinal voxel-based morphometry to 
examine the trajectory of these abnormalities during early stages of illness development. 
 
Method. Unaffected individuals (16–25 years) at high and low familial risk of mood disorder 
underwent structural brain imaging on two occasions 2 years apart. Further clinical 
assessment was conducted 2 years after the second scan (time 3). Clinical outcome data at 
time 3 was used to categorize individuals: (i) healthy controls (‘low risk’, n = 48); (ii) high-risk 
individuals who remained well (HR well, n = 53); and (iii) high-risk individuals who developed 
a major depressive disorder (HR MDD, n = 30). Groups were compared using longitudinal 
voxel-based morphometry. We also examined whether progress to illness was associated 
with changes in other potential risk markers (personality traits, symptoms scores and baseline 
measures of childhood trauma), and whether any changes in brain structure could be indexed 
using these measures. 
 
Results. Significant decreases in right amygdala grey matter were found in HR MDD v. controls 
(p = 0.001) and v. HR well (p = 0.005). This structural change was not related to measures of 
childhood trauma, symptom severity or measures of sub-diagnostic anxiety, neuroticism or 
extraversion, although cross-sectionally these measures significantly differentiated the 
groups at baseline. 
 
Conclusions. These longitudinal findings implicate structural amygdala changes in the 
neurobiology of mood disorder. They also provide a potential biomarker for risk stratification 
capturing additional information beyond clinically ascertained measures. 
 
Introduction 
Bipolar disorder (BD) and major depressive disorder (MDD) are highly heritable mood 
disorders that share a complex overlapping genetic architecture (McGuffin et al. 2003; Liu et 
al. 2011; Schulze et al. 2014). Close relatives of BD patients are also at greater risk of 
developing other major psychiatric conditions, in particular MDD (Shih et al. 2004). A 
substantial proportion of the heritability for mood disorders is explained by a polygenic 
component where many alleles of individually small effect sizes confer risk to BD and MDD in 
aggregate. Other factors, however, also contribute to risk, including stressful life events in 
childhood and personality traits such as higher neuroticism and lower extraversion (Kendler 
et al. 2006). 
 
Both BD and MDD are disorders of emotion regulation and are characterized by episodic 
elevation and/or depression of mood. Difficulties with mood regulation in these disorders are 
likely to derive from disturbances in neural systems mediating emotion processing. 
Neuroimaging studies in patient groups indicate abnormalities in components of the cortico-
limbic network, with particular emphasis on altered structure and function of the amygdala, 
hippocampus and cingulate cortex (Phillips et al. 2003; Hajek et al. 2009; Savitz & Drevets, 
2009; Bora et al. 2012; Sacher et al. 2012). Models propose either a loss or reduction of 
higher-order cognitive control by prefrontal regions over the amygdala, or conversely a 
hyperactive limbic network overriding this cortical control (Phillips et al. 2003). 
 
The majority of neuroimaging studies in mood disorder have, however, been conducted on 
patients with longstanding illness. A number of studies have, however, begun to examine 
structural neuroimaging features in familial high-risk populations, both in BD and MDD (Hajek 
et al. 2009; Baare et al. 2010; Chen et al. 2010; Amico et al. 2011; Karchemskiy et al. 2011; 
Bechdolf et al. 2012; Alemany et al. 2013; Kelley et al. 2013; Eker et al. 2014; Romanczuk-
Seiferth et al. 2014). However, a consensus of findings has yet to emerge, with some studies 
reporting increases in volume of cortico-limbic structures, some reporting decreases or no 
change. Some inconsistency may relate to the crosssectional nature of the studies and issues 
relating to the timing of sampling in relation to overall risk trajectories, along with other 
methodological differences. 
 
There is also a relative paucity of studies examining neuro progressive change, its relationship 
with changing features of illness, and in particular during early phases of illness development. 
It is unclear therefore whether structural abnormalities reported in patient groups are 
confounded by secondary effects of long term illness or medication. Similarly, the timing of 
the onset of these abnormalities and how trait-related features and neurobiology change 
over the early course of illness development remain uncertain. 
These are critical issues from a clinical perspective for informing predictive models of risk, and 
are the focus of the current study. 
 
The Scottish Bipolar Family Study (BFS) is a prospective longitudinal imaging study examining 
young individuals (16–25 years) at high familial risk of mood disorder, along with a group of 
healthy controls with no family history, with the aim of addressing the above issues (Whalley 
et al. 2011). In previous imaging studies on this sample at baseline, when all individuals were 
unaffected, we reported abnormal amygdala function during an executive processing task in 
the high-risk group v. controls (Whalley et al. 2011), along with abnormal cortico-limbic white 
matter connections (Sprooten et al. 2011). Activation of the amygdala was also found to be 
related to cumulative genetic risk for BD using polygenic risk profiling (Whalley et al. 2012). 
Other studies have also reported findings of altered cortico-limbic structure or function in 
unaffected relatives of mood disorder patients (Levesque et al. 2011; Mannie et al. 2014; 
Miskowiak et al. 2015). In terms of neurodevelopmental trajectory, therefore, these findings 
begin to suggest that cortico-limbic abnormalities are not restricted to established illness, nor 
are they related to confounding effects of medication, and indeed may be related to the 
overall burden of genetic risk variants. Whether these abnormalities can distinguish those at 
greatest risk for illness, how they change over the course of illness development, or how they 
relate to other nongenetic risk factors for illness, have yet to be fully determined.  
 
Over the course of the BFS a number of individuals have developed a mood disorder, 
predominantly MDD [defined as meeting formal diagnostic criteria, Diagnostic and Statistical 
Manual of Mental Disorders, 4th edition (DSM-IV)]. How these limbic abnormalities develop 
over early phases of illness has, however, yet to be fully addressed (Whalley et al. 2013; 
Papmeyer et al. 2015). The current study therefore reports longitudinal structural imaging 
findings using the most up-to-date clinical information on the BFS participants (from time 3; 
T3). We utilized voxel-based morphometry approaches to examine prospective longitudinal 
structural changes over time to inform markers of risk of mood disorder (MDD). Based on 
previous findings (Hajek et al. 2009; Bora et al. 2012; Sacher et al. 2012), we hypothesized 
that there would be grey matter loss in the amygdala, hippocampus, anterior cingualate 
cortex and prefrontalgrey matter in those at high familial risk who develop illness v. those 
who are at high familial risk but have remained well, and v. healthy controls. Along with 
longitudinal structural imaging changes we also sought to test whether progress to illness was 
associated with changes in other potential risk markers, namely personality traits of high 
neuroticism and low extraversion, changes in symptoms scores and baseline measures of 
childhood trauma (Heim & Nemeroff, 2001; Peyrot et al. 2014). We also examine whether 
any changes in brain structure could potentially be indexed using these clinically ascertained 
measures. 
 
Method 
Initial baseline recruitment 
Baseline recruitment has been described in full previously (Sprooten et al. 2011; Whalley et 
al. 2011; Papmeyer et al. 2015). Briefly, at the beginning of the study (time 1, T1), individuals 
with a diagnosis of bipolar I disorder were identified by psychiatrists across Scotland. 
Diagnosis was confirmed with the OPCRIT symptom checklist (McGuffin et al. 1991) using data 
from clinical notes and the Structured Clinical Interview for DSM-IV (SCID; First et al. 2002). 
Each affected subject was asked to identify members of close family aged 16–25 years. 
Following informed consent, unaffected individuals with at least one first degree or two 
second-degree relatives with bipolar I disorder were invited to participate. For the majority 
of cases (about 90%) the high-risk individuals were first-degree relatives of the ill family 
member. Only three of the HR well individuals and one HR MDD had (two or more) second-
degree relatives with BD. Unaffected, unrelated comparison subjects with no personal or 
family history of BD were identified from the social groups of the high-risk subjects and 
matched for age, gender and intelligence quotient (IQ) to the high-risk group. Comparison 
subjects were also screened using the SCID (First et al. 2002). Exclusion criteria for both 
groups at initial recruitment included a personal history of major depression, mania or 
hypomania, psychosis, or any major neurological or psychiatric disorder, a history of 
substance dependence, learning disability, or any history of head injury that included loss of 
consciousness and any contraindications to magnetic resonance imaging (MRI). No group 
differences in lifetime substance misuse were observed previously in this sample (Whalley et 
al. 2011). Written informed consent was obtained. The study was approved by the Multi-
Centre Research Ethics Committee for Scotland.  
 
Current study population 
Participants were recruited for the current study as part of the BFS as described above. 
Participants, including controls, have been followed up on three occasions 2 years apart 
(Whalley et al. 2015). Only the first two occasions [T1, time 2 (T2)] contained imaging 
assessments, the third assessment (T3) being primarily a follow-up clinical assessment. All 
participants, controls and high risk, were interviewed by one of two experienced psychiatrists 
(A.M.M., J.E.S.) using the SCID (First et al. 2002) to confirm the lifetime absence of any Axis I 
disorders at T1, and at T2 to determine the presence of any mood disorder meeting diagnostic 
criteria over the intervening period. At T3 diagnostic status was determined either by face-
to-face assessment, or through accessing clinical records at the National Health Service (NHS) 
as to whether a clinical diagnosis had been made or not (Whalley et al. 2015). For a number 
of individuals (n = 9), it was not possible to determine the clinical status at T3, either the 
general practitioner (GP) did not provide details or the GP address was unknown. In the 
absence of further clinical information indicating that they had become unwell, and since they 
had remained well over the previous two assessments, these individuals were presumed to 
have remained well. This, however, necessitated an additional confirmatory analysis 
excluding these individuals reported below. If other disorders were present along with 
depressive features (e.g. borderline personality disorder, n = 1; alcoholism, n = 1; or episodes 
of psychosis, n = 1) these individuals were excluded from the current analysis.  
 
Manic and depressive symptoms were rated using the Young Mania Rating Scale (YMRS; 
Young et al. 1978) and the Hamilton Rating Scale for Depression (HAM-D; Hamilton, 1960), 
and the presence of psychotic symptoms was assessed using the Positive and Negative 
Syndrome Scale (PANSS, Kay et al. 1987). Estimates of trait-liability to mood disorder 
(neuroticism and extraversion) were measured using the NEO Five Factor Inventory (NEO-FFI; 
McCrae & John, 1992). Childhood trauma was measured using the 18-item Childhood Trauma 
Questionnaire (CTQ; Bernstein & Fink, 1988).  
 
The current study concerns structural brain changes between T1 and T2 in relation to the 
development of MDD at any time throughout the study. The final sample consisted of 131 
individuals categorized into three groups: (i) healthy controls who remained well (n = 48; note 
that seven control individuals developed MDD; however, due to small group size these 
individuals were not included in the current analysis); (ii) familial high-risk participants who 
remained well throughout the study (HR well, n = 53); and (iii) familial high-risk participants 
who developed a mood disorder (MDD) at any time throughout the period of study (21 by T2, 
a further nine by T3; HR MDD, n = 30; also of note is that two HR individuals had developed 
BD over the course of the study, similar to above these individuals were not included in the 
current analyses).  
 
The mean interval between T1 and T2 was 2.12 (S.D. = 0.13), 2.24 (S.D. = 0.15) and 2.24 (S.D. 
= 0.19) years for the control, HR well and HR MDD groups, respectively. The mean interval 
between T2 and T3 was 2.73 (S.D.= 0.13), 2.67 (S.D. = 0.14) and 2.66 (S.D. = 0.18) years forthe 
control, HR well and HR MDD groups, respectively. Five individuals from the HR MDD group 
were on antidepressant medication at T2. An additional subsequent confirmatory analysis 
was therefore performed excluding these individuals to explore the confounding effects of 
medication. 
 
Image processing and analysis 
 
All participants were scanned at the Edinburgh University Brain Research Imaging Centre 
(BRIC) on a GE 1.5T Signa scanner (GE Medical). The T1 sequence was a coronal gradient echo 
sequence with the magnetization preparation (MPRAGE) yielded 180 contiguous 1.2-mm 
coronal slices (matrix = 192 × 192; field of view = 24 cm; flip angle 8°).  
 
After reconstruction from raw dicom format to nifti via dcm2nii, structural data were analysed 
with FSL–voxel-based morphometry (FSL-VBM) (Douaud et al. 2007) 
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLVBM), an optimized VBM protocol (Good et al. 2001; 
Smith et al. 2004) carried out within the FSL environment (Smith et al. 2004). Briefly, all 
structural images, one for each participant and time point, were brainextracted and grey 
matter-segmented before being registered to the MNI 152 standard space using nonlinear 
registration. The resulting images were then averaged and flipped along the x-axis to create 
a left– right symmetric, study-specific grey matter template. Next, all native grey matter 
images were non-linearly registered to this study-specific template and ‘modulated’ to 
correct for local expansion (or contraction) due to the non-linear component of the spatial 
transformation. The modulated grey matter images were then smoothed with an isotropic 
Gaussian kernel with a sigma of 3 mm. The choice of smoothing kernel was selected in order 
to maximize the ability to detect differences in the medial temporal lobe regions as described 
in our prior hypotheses. The smoothed, normalized grey matter images were compared 
longitudinally between the three groups: controls, HR well and HR MDD. This was done using 
a voxel-wise general linear model (GLM) with a repeated-measures design including all three 
groups over both time points. The model was applied using permutation-based 
nonparametric testing in the FSL package randomise The analysis plan was to examine 
differences in longitudinal change over time between the three groups (controls, 
HR well and HR MDD). 
 
Results in grey matter were considered significant for p < 0.05, after correction for multiple 
comparisons using the threshold-free cluster enhancement (TFCE) approach (Smith & Nichols, 
2009) in the FSL randomize package which avoids using an arbitrary threshold for the initial 
cluster formation. Based on our a priori hypothesis, small volume corrections were applied 
for the bilateral amygdala, hippocampus and anterior cingulate cortex created using the 
Harvard–Oxford sub-cortical structural atlas (Desikan et al. 2006). Prefrontal abnormalities 
were examined at the wholebrain level. All coordinates are quoted in Montreal Neurological 
Institute (MNI) convention (http://www. mni.mcgill.ca) and images are overlaid onto a 
standard brain in MNI space using FSLView software package. Demographic and clinical data 
were analysed using one-way analyses of variance, χ2 tests or Kruskal– Wallis tests where 
appropriate using SPSS (USA). 
 
Relationship between grey matter change and individual risk markers  
We subsequently examined the association between imaging changes over time and 
measures of childhood trauma, trait-liability and mood state. Imaging data were extracted 
using the significant clusters of difference (mean of the cluster) between groups and 
subsequently related to total CTQ scores at baseline, measures of depressive symptoms (from 
HAM-D scores), and measures of trait-liability (neuroticism and extraversion) using both 
baseline and change in scores over time. This was performed in SPSS using correlation analysis 
on the whole sample whilst controlling for group status. 
 
Results 
Demographic data 
Demographics, clinical details and behavioural measures are presented in Table 1. Groups did 
not differ with respect to age, gender or IQ as measured by the National Adult Reading Test 
(NART; Nelson, 1982). For the HR-MDD individuals (n = 30), at T2, nine individuals from this 
group were well (becoming ill later) and 21 individuals were diagnosed as MDD (all assessed 
using the SCID). Of the latter, 12 individuals were classed as single episode and nine were 
classed as recurrent. Three individuals scored >15 other HAM-D. The highest score for the 
YMRS was score of 5 in one individual; the remaining individual scored 0–2. For the PANSS 
positive scores, two individual scored 9; the remainder scored 7–8 (7 being equivalent to null). 
 
At T3, 10 individuals were classed as well, one individual was deceased and the remainder 
were classed as MDD. Of the latter group, seven diagnoses were determined through GP 
contact and for whom we could not determine further detailed subtype diagnoses. 
Of those 14 who were MDD assessed using the SCID, two were single episode and 12 were 
classed as recurrent. Three individuals scored >15 on the HAM-D. The highest score on the 
YMRS was a score of 4 in one individual; the remaining subjects scored 0–2. For the PANSS 
positive, one individual scored 14, one scored 12, and the remainder scored 7–8. 
 
Between-group differences in brain structure Comparisons of groups at the whole-brain 
level did not reveal any significant longitudinal grey matter changes over time between the 
groups in the prefrontal cortex or in any other region. Region of interest analysis in the 
anterior cingulate cortex also did not reveal any significant group differences. However, 
significant differences were reported in the right amygdala using the a priori region of 
interest approach [cluster extent = 488 mm3, peak MNI coordinates = (57, 56, 27), pcorr < 
0.017; see Fig. 1]. This cluster also overlapped with the hippocampal region of interest; 
however, since the bulk of this cluster and the peak was centered in the amygdala we refer 
to the result as such. 
 
Formal pair-wise comparison of the extracted amygdala data (mean of the cluster) indicated 
significant group × time interactions between the controls and HR MDD (p = 0.001, F = 
12.954), between the HR well and HR MDD (p = 0.005, F = 8.197), but not between the 
controls and HR well groups. Graphs of extracted amygdala grey matter for the cluster of 
difference revealed that there was a small increase in both the control and HR well groups 
between T1 and T2; by contrast, the HR MDD group demonstrated a reduction in grey matter 
over the two time points (Fig. 2). Removing the five individuals who were on medication at 
T2 did not alter the findings of grey matter differences in the amygdala over time between 
groups (p = 0.003, F = 6.18), nor did excluding the nine participants in the HR well group who 
were presumed well due to unavailable follow-up clinical data at T3 (p = 0.002, F = 6.66). 
Similarly, removing the individuals who became ill at T3 did not alter the findings (p = 
0.002, F = 6.45). 
 
 
Examining findings cross-sectionally at T1 and T2 separately indicated no significant 
differences at the whole-brain level between the groups, nor for the anterior cingulate region 
of interest. There were, however, significant group differences for the amygdala at T1 but not 
at T2 based on extracted data (T1: F = 3.363, p = 0.038; T2: F = 0.709, p = 0.494). Pair-wise t 
test comparisons indicated significant differences between controls and HR MDD at T1 only 
(controls v. HR MDD T1: F = 2.542, p = 0.013; T2: F = 0.101, p = 0.274; HR well v. HR MDD T1: 
F = 1.810, p = 0.074; T2: F = 1.055, p = 0.294; controls v. HR well, T1: F = 
1.024, p = 0.310, T2: F = 0.172, p = 0.864). 
 
Between-group differences in longitudinal symptom severity and trait-liability measures 
 
There were no significant differences between the groups in terms of longitudinal change in 
symptom severity scores or personality measures between T1 and T2 (HAM-D χ2 = 2.971, p = 
0.226; neuroticism χ2 = 0.476, p = 0.788; extraversion χ2 = 2.879, p = 0.237). time point, and 
these were significantly higher than controls and HR well individuals; see Table 1.  
 
There were also significant differences between the three groups for baseline measures of 
neuroticism (p < 0.001), extraversion (p = 0.003) and childhood trauma (CTQ total, p = 0.004); 
see Table 1. Specifically, the HR MDD group showed the highest level of neuroticism and CTQ, 
and lowest levels of extraversion. For neuroticism, extraversion and CTQ, pair-wise 
comparisons indicated significant differences between the controls and HR MDD groups (p < 
0.001, Z = 3.563; p = 0.001, Z = 3.293; p = 0.001, Z = 3.340, respectively), between the HR well 
and HR MDD groups (p < 0.001, Z = 3.714; p = 0.016, Z = 2.407; p = 0.039, Z = 2.861, 
respectively), but not between the controls and HR well individuals. time point, and these 
were significantly higher than controls and HR well individuals; see Table 1. There were also 
significant differences between the three groups for baseline measures of neuroticism (p < 
0.001), extraversion (p = 0.003) and childhood trauma (CTQ total, p = 0.004); see Table 1. 
Specifically, the HR MDD group showed the highest level of neuroticism and CTQ, and lowest 
levels of extraversion. For neuroticism, extraversion and CTQ, pair-wise comparisons 
indicated significant differences between the controls and HR MDD groups (p < 0.001, Z = 
3.563; p = 0.001, Z = 3.293; p = 0.001, Z = 3.340, respectively), between the HR well and HR 
MDD groups (p < 0.001, Z = 3.714; p = 0.016, Z = 2.407; p = 0.039, Z = 2.861, respectively), but 
not between the controls and HR well individuals. 
 
 
Fig. 1. Longitudinal structural change within the amygdala as assessed by voxel-based 
morphometry. Decreases over time in high-risk individuals who develop major depressive 
disorder over the course of the study v. those that remain well, and healthy controls over a 
2-year inter-scan period: (a) coronal section; (b) sagittal section. 
 
As expected, however, there were significant differences between groups for cross-sectional 
measures of depression indexed by the HAM-D, with the HR MDD group scoring highest 
across all time points (T1, p < 0.01; T2, p < 0.01; and T3, p = 0.01). Further, pair-wise t tests 
show that significant differences existed between controls and HR MDD (T1, p < 0.001; 
T2, p < 0.001 and T3, p = 0.02) and between HR well and HR MDD (T1, p = 0.001; T2, p < 0.001; 
and T3, p = 0.04). There were no significant differences between groups in terms of mania 
scores determined from the YMRS for any assessment points. The HR MDD group also 
demonstrated significantly increased levels of sub-diagnostic anxiety as measured by the 
Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Auto questionnaire 
(TEMPS-A) at each time point, and these were significantly higher than controls and HR well 
individuals; see Table 1. There were also significant differences between the three groups for 
baseline measures of neuroticism (p < 0.001), extraversion (p = 0.003) and childhood trauma 
(CTQ total, p = 0.004); see Table 1. Specifically, the HR MDD group showed the highest level 
of neuroticism and CTQ, and lowest levels of extraversion. For neuroticism, extraversion and 
CTQ, pair-wise comparisons indicated significant differences between the controls and HR 
MDD groups (p < 0.001, Z = 3.563; p = 0.001, Z = 3.293; p = 0.001, Z = 3.340, respectively), 
between the HR well and HR MDD groups (p < 0.001, Z = 3.714; p = 0.016, Z = 2.407; p = 0.039, 
Z = 2.861, respectively), but not between the controls and HR well individuals. Relationship 
between imaging findings and symptom severity and trait-liability measures 
We examined the relationship between the VBM measures of amygdala grey matter change 
over time and measures of depression from the HAM-D (baseline, T2, and change in score 
between T1 and T2), anxiety (from the TEMPS-A baseline, T2 and change in score between T1 
and T2) neuroticism, extraversion (baseline, T2 and change in score between T1 and T2), and 
CTQ (baseline only). There were no significant associations in the whole sample controlling 
for group status, nor within groups separately. 
 
Discussion 
 
In the current study we demonstrated longitudinal structural decreases over time in the 
amygdala in a group of individuals who were at high familial risk of developing a mood 
disorder and who became ill over the course of the study, v. high-risk individuals who 
remained well, and healthy controls with no family history of mood disorder. The findings 
indicate that dynamic structural changes in the amygdala are associated with the 
development of MDD in this young sample. Measures of symptom severity, sub-diagnostic 
anxiety, neuroticism and extraversion, and CTQ significantly differentiated the groups at 
baseline prior to illness, and therefore may therefore constitute vulnerability markers of 
illness. However, changes in these non-imaging risk factors between assessments did not 
associate with illness development, nor did they relate significantly to the imaging findings. 
Taken together therefore these findings indicate that imaging measures may more closely 
follow the dynamic route to illness than clinically ascertained measures of risk. 
 
 
 
Converging lines of evidence suggest that the amygdala plays an important role, along with 
wider prefrontal and limbic networks, in responding to emotional salience of stimuli. The 
amygdala is therefore a key structure in the formation and stability of affective states 
(LeDoux, 2000). Previous imaging studies of the amygdala in MDD have most consistently 
demonstrated abnormally increased functional activation in response to negative or non-
emotional stimuli in patient groups, also seen in unaffected relatives (Drevets, 2003; Drevets 
et al. 2008; Whalley et al. 2011; Swartz et al. 2014), along with impaired prefrontal–amygdala 
connectivity (Matthews et al. 2008; Almeida et al. 2009). Such circuits are therefore 
considered key to the emotion-regulation difficulties experienced in the disorder (Phillips et 
al. 2003). Structural studies comparing cases and controls have, however, been generally less 
directionally consistent, or indeed report no differences (Frodl et al. 2008; Arnone et al. 2012). 
There is growing evidence of increased volumes of the amygdala early on in the disease 
course, for example in first-episode (Frodl et al. 2002, 2003), and in high-risk cohorts (Boccardi 
et al. 2010; Rao et al. 2010; Saleh et al. 2012; Romanczuk- Seiferth et al. 2014), indicating 
potential differences in the trajectory of developmental processes. Although we did not 
report significant cross-sectional baseline differences in the amygdala in the current study, 
we do report dynamic structural changes within the right amygdala around the period of 
illness development which manifested as a decrease over time in those who developed MDD. 
In those who remained well, and in the healthy control group, there was an increase in grey 
matter over time in the amygdala which we therefore interpret as reflecting normal 
neurodevelopment in this region in this relatively young cohort of individuals who are still 
reaching levels of neurobiological maturity. This is notably highly consistent with a previous 
study reporting that adolescents during early phases of the mood disorder do not exhibit 
normal increases in amygdala volume that occur during healthy adolescent 
neurodevelopment (Bitter et al. 2011). 
 
This finding was only significant for the right amygdala. Previous studies examining amygdala 
structure in depression have provided equivocal results regarding hemispheric lateralization 
(Hamilton et al. 2008). Further, given the paucity of other longitudinal studies, we believe that 
currently any conclusions about laterality should be undertaken with caution. Regardless, the 
current study adds to a currently rather limited literature of longitudinal change in brain 
structure associated with the onset of mood disorder in young participants at increased risk 
(Whittle et al. 2015). The findings begin to indicate timelines for abnormal neurodevelopment 
during the early course of illness. Whether such structural changes are a cause or 
consequence of active disease processes, however, remains unclear. Also, whether such 
changes are able to inform important clinical distinctions can only be determined with further 
follow-up of the cohort. For example, whether it is possible to distinguish those who have a 
single episode of unipolar depression v. those who manifest a more severe recurrent course, 
or indeed who go on to develop BD or other mental health problems. Finally, how such 
abnormalities relate to wider prefrontal circuitry abnormalities reported in patients has also 
yet to be established. 
 
One other main factor that has previously been associated with the risk of developing mood 
disorder is anxiety disorder, which has a particularly strong relevance in the current context 
given its reported association with the amygdala. We would like to stress, however, that at 
recruitment any individuals who met diagnostic criteria for an anxiety disorder were not 
included in the study. Further, we report no association either between the change in anxiety 
scores from the TEMPS-A and changes in the amygdala grey matter, or any significant 
associations crosssectionally. We cautiously conclude therefore that these findings represent 
change associated with the development of MDD rather than to concurrent anxiety 
Features 
 
We also acknowledge several limitations of the current study. The longitudinal nature of such 
a study spanning 6+ years and the necessity for utilizing a consistent imaging strategy has 
meant that imaging protocols can begin to look dated in terms of slice thickness and field 
strength. However, we believe this is inherent to any long-term, longitudinal study and does 
not affect the valuable contribution of the data.  
Also, although the presence of a family history of mental illness is one of the highest risk 
factors for depression, other factors also contribute to the overall pattern of risk. Among 
these are early stressful life events, and the personality traits of neuroticism (high) and 
extraversion (low) which are thought to relate to maladaptive cognitive and emotional 
processing (Heim & Nemeroff, 2001; MacMillan et al. 2001; Kendler et al. 2006; Chan et al. 
2007; Hovens et al. 2010). Notably, these measures at baseline differentiated those at high 
risk who became ill v. those who remained well over the course of 4 years, indicating the 
importance of these measures in informing wider models of risk prediction. Although we 
consider it an important finding that individuals who go on to develop MDD at follow-up have 
significantly increased levels of symptoms as measured by the HAM-D and increased 
neuroticism since they may indicate important predictors of subsequent illness, we also note 
that this could equally reflect the prodromal phase of a mood disorder. We stress, however, 
than no individuals met diagnostic criteria for a mood disorder at study entry. In the current 
study, however, none of these measures was directly related to the structural imaging 
findings, nor were changes in these scores associated with the developmental trajectory of 
illness onset. We interpret these finding therefore as suggesting that imaging measures are 
more sensitive to changes associated with the dynamic route to illness than these clinically 
ascertained measures of risk. We also note as an additional limitation that the lack of 
relationship between change in clinical and trait features of the disorder with imaging 
features could be attributable to lack of power (limited range of change in the scores), or to 
the fact that these measures were not specifically designed to measure change per se. In 
particular, personality features are considered to be stable traits across the lifespan. The lack 
of associations between these measures should therefore be viewed cautiously. 
 
A particular strength of the current study was the use of a young, relatively large, well-
characterized cohort followed up over 4+ years on whom we are continuing to collect data. 
By the very nature of the cohort the clinical picture is one of dynamic change. 
It is possible, if not likely, that for some individuals for whom an early diagnosis of MDD may 
ultimately herald a diagnosis of BD, as was the case for two individuals in the study (Hillegers 
et al. 2005). These findings should therefore be considered in this context. We also note that 
conversion rates (for MDD) are similar to those reported in other prospective longitudinal 
studies examining the clinical course of young relatives of bipolar individuals (Hillegers et al. 
2005; Duffy et al. 2009, 2014). The study by Duffy et al. (2014), for example, reported a 
cumulative incidence of 32 out of 229 high-risk individuals, and eight out of a sample of 86 
control participants who developed MDD, but only three individuals from the high-risk group 
developed BD (and no controls), consistent with the findings reported here. The continued 
clinical longitudinal follow-up of these high-risk samples will make important contributions to 
the understanding of early phases of affective disease pathways. One other criticism could be 
that since there is a decrease over time in the HR MDD group, and there are no significant 
differences between the groups cross-sectionally at T2, this could represent regression to the 
mean. Ongoing scanning assessment of the individuals will provide a clearer picture of 
whether there is continued progressive decline in the ill group. Finally, we also highlight the 
practical difficulties in performing such large-scale prospective longitudinal cohort imaging 
studies, particularly relating to cumulative attrition over the course of the study. For this 
reason it was necessary for us to determine diagnostic status for a small number of individuals 
based on GP correspondence at T3. We acknowledge that this as a limitation in that we 
consequently have fewer symptom-related and subtype details for these participants. 
 
Overall our findings suggest that development of MDD in a cohort of individuals at high 
familial risk of BD is related to the decreasing amygdala grey matter around the time of illness 
onset. Other factors such as increased levels of childhood trauma, increased neuroticism and 
decreased extraversion appeared to distinguish groups at baseline; however, longitudinal 
change in these scores did not relate to the development of MDD, suggesting that imaging 
measures may capture additional information beyond clinically ascertained measures of risk 
and may be a useful marker of illness development. 
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